1987
Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation.
Johnson D, Thompson J, Corwin J, Mosley K, Smith M, de los Reyes R, Daly M, Petty A, Lamaster D, Pierson W. Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation. Journal Of Clinical Oncology 1987, 5: 783-9. PMID: 3553437, DOI: 10.1200/jco.1987.5.5.783.Peer-Reviewed Original ResearchConceptsAutologous bone marrow transplantationHigh-dose BCNUBone marrow transplantationSignificant survival advantageMarrow transplantationMedian survivalMalignant gliomasBone marrowSurvival advantageConsecutive historical control patientsDied of pulmonary hemorrhageWeeks of initial surgeryHigh-grade malignant gliomasBone marrow infusionProlongation of survivalPoor performance statusAbsolute granulocyte countHistorical control patientsAutologous bone marrowMalignant glial tumorsHistorical control groupEmpirical antibioticsBrain irradiationInitial surgeryMarrow infusion
1986
Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer.
Ihde D, Deisseroth A, Lichter A, Bunn P, Carney D, Cohen M, Veach S, Makuch R, Johnston-Early A, Abrams R. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 1443-54. PMID: 3020181, DOI: 10.1200/jco.1986.4.10.1443.Peer-Reviewed Original ResearchConceptsExtensive-stage SCLC patientsProphylactic cranial irradiationComplete responseAutologous bone marrowPartial responseSCLC patientsModality therapyTumor regressionMedical conditionsExtensive-stage small-cell lung cancer patientsExtensive-stage small-cell lung cancerSmall cell lung cancer patientsAutologous bone marrow infusionMajor non-hematologic toxicitySmall cell lung cancerExtensive-stage patientsNon-hematologic toxicitiesWeeks of cyclophosphamideWeeks of vincristineBone marrow infusionGood medical conditionPoor medical conditionLung cancer patientsBetter tumor regressionCranial irradiation
1983
Intensive combined modality therapy including low-dose TBI in high-risk ewing's sarcoma patients
Kinsella T, Glaubiger D, Diesseroth A, Makuch R, Waller B, Pizzo P, Glatstein E. Intensive combined modality therapy including low-dose TBI in high-risk ewing's sarcoma patients. International Journal Of Radiation Oncology • Biology • Physics 1983, 9: 1955-1960. PMID: 9463099, DOI: 10.1016/0360-3016(83)90368-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgranulocytosisAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBone NeoplasmsChildCombined Modality TherapyCyclophosphamideDactinomycinDisease-Free SurvivalFemaleHumansLung NeoplasmsMaleNeoplasm Recurrence, LocalSarcoma, EwingVincristineWhole-Body IrradiationConceptsAutologous bone marrow infusionHigh-risk Ewing's sarcoma patientsTotal body irradiationEwing's sarcoma patientsLow-dose total body irradiationComplete clinical responseSarcoma patientsGranulocyte recoveryClinical responseModality therapyModality protocolMedian disease-free intervalMicroscopic systemic diseaseMonths of relapseBone marrow infusionCells/mm3Disease-free intervalPoor prognosis groupOnly distant metastasesTotal granulocyte countConsolidative therapyInduction therapyInitial relapseMaintenance chemotherapySecond relapse
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply